Request Demo

Last update 30 Jul 2026

Amphotericin B

Last update 30 Jul 2026

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

AmB, HC1507G2, SinuNase

+ [17]

Target

Ergosterol

Action

modulators

Mechanism

Ergosterol modulators(Ergosterol modulators)

Therapeutic Areas

Infectious DiseasesNervous System DiseasesCardiovascular Diseases+ [4]

Active Indication

AspergillosisCryptococcosisLeishmaniasis, Visceral+ [11]

Inactive Indication

Acute Lymphoblastic LeukemiaAcute Myeloid LeukemiaCandidiasis, Chronic Mucocutaneous+ [8]

Originator Organization

Vestar Development Co.

Active Organization

Sumitomo Pharma Co., Ltd.Southern XP IP Pty Ltd.

CSPC Pharmaceutical Group Ltd.

+ [7]

Inactive Organization

Matinas BioPharma Nanotechnologies, Inc.

CSPC Zhongqi Pharmaceutical Technology (Tianjin) Co., Ltd.

Enzon Pharmaceuticals, Inc.

+ [2]

License Organization

Dr. Reddy's Laboratories Ltd.

SAM CHUN DANG PHARM Co., Ltd.Matinas BioPharma, Inc.

+ [7]

Drug Highest PhaseApproved

First Approval Date

(01 Jan 1958),

Mycoses

RegulationFast Track (United States), Orphan Drug (United States), Orphan Drug (European Union), Qualified Infectious Disease Product (United States)

Structure/Sequence

Molecular FormulaC47H73NO17

InChIKeyAPKFDSVGJQXUKY-INPOYWNPSA-N

CAS Registry1397-89-3

141

Clinical Trials associated with Amphotericin B

NCT06525389

/ Not yet recruitingPhase 3IIT

Liposomal Amphotericin B and Flucytosine Antifungal Strategy for Talaromycosis (LAmB-FAST)

LAmB-FAST is a factorial randomized controlled trial simultaneously testing two interventions in one trial. LAmB-FAST seeks to inform treatment guidelines on the induction and maintenance therapy of HIV-associated talaromycosis (formerly called penicilliosis) and will answer the following three questions:
1. Is induction therapy using a single 10 mg/kg dose of liposomal amphotericin B (LAmB) is more effective than 14 days of the conventional deoxycholate amphotericin B (DAmB)?
2. Is adding flucytosine (5FC) to amphotericin B more effective than amphotericin B alone?
3. Is HIV viral load guided stopping of itraconazole maintenance therapy as effective as the current CD4 guided strategy in the prevention of talaromycosis relapse?

Start Date01 Jul 2026

Sponsor / Collaborator

Duke University

[+4]

NCT07559032

/ Not yet recruitingNot ApplicableIIT

A Multicenter, Prospective, Observational Study to Evaluate the Efficacy and Safety of Amphotericin B in the Treatment of Breakthrough Invasive Fungal Disease in Hematological Patients Receiving Triazole Prophylaxis

The goal of this clinical trial is to learn if amphotericin B works to treat breakthrough invasive fungal disease (IFD) in patients with hematological diseases who have received azole-based prophylaxis. It will also learn about the safety of amphotericin B in this population.
The main questions it aims to answer are:
1. What is the overall response rate (complete remission + partial remission) of amphotericin B in treating breakthrough IFD after azole prophylaxis?
2. What medical problems do participants have when taking amphotericin B?
3. What is the 6-week (42-day) overall survival rate after starting treatment?
This is a single-arm, prospective study. Participants will:
1. Receive intravenous liposomal amphotericin B (3-5 mg/kg daily) for 4-6 weeks.
2. Undergo weekly clinical and laboratory assessments, including serum G/GM tests, microbiology tests, and imaging (CT) at 2, 4, and 6 weeks.
3. Have safety monitoring including liver and kidney function, electrolytes, and ECG.
4. Be followed for treatment response and survival.

Start Date01 Apr 2026

Sponsor / Collaborator

Peking University People's Hospital

NCT07532850

/ Not yet recruitingNot ApplicableIIT

Study on the Pharmacokinetic Characteristics, Safety, and Efficacy of Liposomal Amphotericin B in Critically Ill Patients With Invasive Fungal Infections Undergoing Plasma Exchange Therapy

The goal of this prospective study is to describe the pharmacokinetic characteristics of liposomal amphotericin B during plasma exchange therapy for severe invasive fungal infections in Chinese patients, preliminarily explore the influencing factors of in vivo exposure variability of liposomal amphotericin B, and integrate the findings with efficacy and safety outcomes.
The main questions it aims to answer is: Clarifying the correlation between the concentration, efficacy, and safety of different forms of liposomal amphotericin B in a special population, explore the changes in drug concentration mediated by plasma exchange, elucidate the mechanism of individual differences in efficacy and the optimal dosage, in order to provide a basis for personalized treatment of liposomal amphotericin B.
The study plans to collect pharmacokinetic samples from 10 adult (aged ≥ 18 years) severe invasive fungal infection patients receive liposomal amphotericin B who undergo plasma exchange therapy.

Start Date30 Mar 2026

Sponsor / Collaborator-

100 Clinical Results associated with Amphotericin B

100 Translational Medicine associated with Amphotericin B

100 Patents (Medical) associated with Amphotericin B

21,265

Literatures (Medical) associated with Amphotericin B

31 Dec 2026·Virulence

The cyclin dependent kinase (CDK)7 inhibitor BS-181 inhibits pathogenic Cryptococcus species, causing G ₂ /M arrest and a splicing defect

Article

Author: Bowring, Bethany ; Hewitt, Kim ; Halliday, Catriona L ; Chen, Sharon C-A ; Sethiya, Pooja ; Dinh, Hue ; Djordjevic, Julianne Teresa ; Parsania, Chirag ; Cain, Amy K ; Desmarini, Desmarini

The fungal priority pathogen and basidiomycete, Cryptococcus neoformans (Cn), causes lung and brain infection in predominantly immuno-compromised individuals and there is an urgent need for new treatment options. The pyrazolopyrimidine-based cyclin dependent kinase (CDK)7 inhibitor, BS-181, has anticancer properties, but its antifungal activity has not been investigated. We show that cryptococcal CDK7 more closely resembles the human enzyme than that of ascomycetes, and that BS-181 inhibits its activity. BS-181 inhibited growth of both Cn and Cryptococcus gattii (Cg), but not ascomycete fungi and delayed progression through the G₂/M phase of the cell cycle. Transcriptomic analysis revealed that BS-181 induces splicing defects leading to elevated intron retention within the transcriptome and also suppresses translational processes. BS-181 displayed additive or synergistic activity with licensed antifungals against laboratory and clinical Cn and Cg strains, most notably with amphotericin B where synergy (2-4-fold reduction in the amphotericin B MIC) was achieved using low-sub micromolar concentrations of BS-181. Compared with either drug alone, BS-181-AmB combination therapy provided greater protection against Cn infection in a wax moth model (p ≤ 0.032) and extended survival of Cn-infected mice. These findings demonstrate that CDK7 inhibitors, already of interest as anticancer agents, could be repurposed to prevent or treat opportunistic fungal infections in cancer patients when combined with licensed antifungals limited by either toxicity or resistance.

31 Dec 2026·Virulence

Genomic epidemiological patterns and antifungal resistance profiles of Candidozyma auris in China: Spatiotemporal dynamics and persistent colonization

Article

Author: Cao, Junmin ; Qin, Cong ; Gu, Danxia ; Zhang, Rong ; Wang, Xiang-Yu ; Zhou, Hongwei ; Li, Ruichao

Candidozyma auris (C. auris) is an emerging multidrug-resistant fungal pathogen with major global public health implications. However, the clinical characteristics, clade-specific genomic variation, resistance-associated SNP patterns, and transmission dynamics of C. auris in China remain insufficiently understood. We retrospectively analyzed clinical data from 22 intensive care unit patients colonized or infected with C. auris and performed antifungal susceptibility testing and whole-genome sequencing (WGS) on 25 isolates. All isolates were resistant to fluconazole, and 80% were resistant to amphotericin B, whereas echinocandin susceptibility remained intact. Phylogenetic analysis assigned the isolates to Clade I (n = 19) and Clade III (n = 6). SNP analysis revealed marked clade-specific differentiation in resistance-associated genes, with ERG11 Y132F enriched in Clade I and ERG11 alterations, including VF125AL, enriched in Clade III. Additional variants in ERG2, CDR1, TAC1a, and TAC1b also showed clade-biased distributions and frequent co-occurrence. However, no significant association was observed between individual SNPs or mutation burden and antifungal susceptibility phenotypes. To investigate transmission dynamics, we conducted comparative genomic and phylogeographic analyses using 210 C. auris genomes. Major inbound introductions into China were inferred from Canada and South Korea to Guangdong and from Pakistan to Beijing, while phylogeographic modeling suggested that Beijing and Guangdong may have served as key nodes for subsequent domestic spread. These findings highlight the importance of integrated genomic surveillance for tracking C. auris dissemination and informing targeted infection control strategies.

31 Dec 2026·Virulence

Repurposing the antispasmodic drug pinaverium bromide as a novel antifungal agent and synergist against Candida albicans

Article

Author: Quan, Keao ; Li, Binglei ; Zeng, Liping ; Feng, Ganzhu ; Yao, Jing ; Shi, Ting ; Hang, Xudong ; Yang, Zhiyu ; Bi, Hongkai ; Xu, Jingchen ; Chen, Tianyu

Fungal infections represent a significant and growing threat to public health, exacerbated by an expanding population of immunocompromised individuals and the increasing prevalence of resistance to conventional antifungal agents. Drug repurposing offers a strategic and efficient pathway for antifungal discovery, leveraging existing pharmacotherapies to reduce development costs and mitigate safety risks. This study evaluated the antifungal potential of pinaverium bromide, an FDA-approved antispasmodic drug for functional gastrointestinal disorders, against the prevalent pathogen Candida albicans. Our in vitro analyses revealed that pinaverium bromide demonstrated standalone antifungal activity and acted synergistically with amphotericin B or azole drugs. Moreover, it effectively attenuated key virulence factors of C. albicans, including hyphal formation and biofilm development. The therapeutic efficacy of both monotherapy and combination therapy with amphotericin B or voriconazole was validated in two murine models of systemic candidiasis. Mechanistically, pinaverium bromide disrupted mitochondrial function, induced apoptotic cell death, and impaired iron homeostasis in C. albicans. When combined with amphotericin B, it potentiated the drug's effect by amplifying reactive oxygen species accumulation and enhancing membrane permeabilization. These findings support the potential of pinaverium bromide as a novel antifungal agent, either when used alone or in combination with established antifungal therapies.

119

News (Medical) associated with Amphotericin B

28 Jun 2026

·www.biospace.com

Matinas BioPharma Receives Notice of Non-Compliance with NYSE American Continued Listing Standards and Acceptance of Plan to Regain Compliance

BEDMINSTER, N.J., June 26, 2026 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (the “Company”) (NYSE American: MTNB) announced today that on June 24, 2026, it received a notice (the “Notice”) from the NYSE American LLC (the “NYSE American”) stating that the Company is not in compliance with the NYSE American continued listing standards set forth in Section 1003(a)(ii) of the NYSE American Company Guide (the “Company Guide”) requiring a company to have stockholders’ equity of at least $4.0 million if it has reported losses from continuing operations and/or net losses in three of its four most recent fiscal years. As of March 31, 2026, the Company had stockholders’ equity of $3.02 million and has had losses in the most recent five fiscal years ended December 31, 2025. As previously disclosed, the Company is also not in compliance with Section 1003(a)(iii) of the Company Guide requiring a company to have stockholders’ equity of at least $6.0 million if it has reported losses from continuing operations and/or net losses in its five most recent fiscal years. As of December 31, 2025, the Company had stockholders’ equity of $4.83 million and has had losses in the most recent five fiscal years ended December 31, 2025. Due to its non-compliance with Sections 1003(a)(ii) and 1003(a)(iii) of the Company Guide, the Company is subject to the procedures and requirements of Section 1009 of the Company Guide. On May 4, 2026, the Company submitted a plan (the “Plan”) to the NYSE American advising of actions it has taken or will take to regain compliance with the continued listing standards. The Notice indicated that the NYSE American staff had determined to accept the Plan and grant the Company a plan period through October 2, 2027 (the “Plan Period,” and such date, the “Plan Period Deadline”). Accordingly, the Company is able to continue its listing during the Plan Period and will be subject to periodic reviews, including quarterly monitoring, for compliance with the Plan until it has regained compliance. However, there can be no assurance that the Company will be able to achieve compliance with such standards within the Plan Period. If the Company is not in compliance with the continued listing standards by the Plan Period Deadline, or if the Company does not make progress consistent with the Plan during the Plan Period, then NYSE American staff may initiate delisting proceedings as appropriate. The Company may appeal a staff delisting determination in accordance with Section 1010 and Part 12 of the Company Guide. The Notice has no immediate impact on the listing of the Company’s shares of common stock, which will continue to be listed and traded on the NYSE American, subject to the Company’s compliance with the other listing requirements of the NYSE American. The Notice does not affect the Company’s ongoing business operations or its reporting requirements with the Securities and Exchange Commission. About Matinas BioPharma Matinas BioPharma is a biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology. About MAT2203 Matinas BioPharma’s MAT2203 is a potential oral broad-spectrum treatment for invasive deadly fungal infections. Although amphotericin B is a fungicidal agent, it is currently only available through an intravenous route of administration, which is known to be associated with several significant safety issues such as renal toxicity and anemia due to very high circulating levels of amphotericin B. MAT2203 has the potential to overcome the significant limitations of the currently available amphotericin B products due to its targeted oral delivery. Combining comparable fungicidal activity with targeted delivery results in a lower risk of toxicity and potentially creates the ideal antifungal agent for the treatment of invasive fungal infections. MAT2203 was successfully evaluated in the completed Phase 2 EnACT study in HIV patients suffering from cryptococcal meningitis, meeting its primary endpoint and achieving robust survival. MAT2203 was planned to be further evaluated in a single Phase 3 registration trial as an oral step-down monotherapy following treatment with AmBisome (liposomal amphotericin B) compared with the standard of care in patients with invasive aspergillosis who have limited treatment options. For more information, please visit . Forward-Looking Statements This release contains “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, contained in this release are forward-looking statements. Forward-looking statements contained in this release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “suggest,” “target,” “aim,” “should,” “will,” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on the Company’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict, including with respect to the Company’s plans related to regaining compliance with the NYSE American’s continued listing standards. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. For a further discussion of risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of the Company in general, see the risk disclosures in the Annual Report on Form 10-K of the Company for the year ended December 31, 2025 and in other filings made with the Securities and Exchange Commission by the Company. All such forward-looking statements speak only as of the date they are made, and the Company undertakes no obligation to update or revise these statements, whether as a result of new information, future events or otherwise. CONTACT: Investor Contact Jerome D. Jabbour Chief Executive Officer (908) 484-8805 operations@matinasbiopharma.com

Phase 2Phase 3

24 May 2026

·www.biospace.com

Gilead Sciences and World Health Organization Expand Collaboration to Help Eliminate Visceral Leishmaniasis, a Fatal Parasitic Disease

Gilead Sciences, Inc. (Nasdaq: GILD) today announced a renewed five-year collaboration with the World Health Organization (WHO), committing funding, strategic support and product donations to accelerate progress toward eliminating visceral leishmaniasis (VL), also known as kala-azar. VL, the second deadliest parasitic disease after malaria, is a sandfly-borne illness that attacks internal organs and can be fatal if untreated. The expanded agreement aims to improve access to life-saving diagnostic services and treatment for some of the world's most vulnerable communities, with a sharpened focus on high-burden countries in East Africa. Gilead is committed to improving global health by advancing innovative treatments and partnering with organizations such as WHO to broaden access to medicines and help eliminate diseases like VL. "Ending visceral leishmaniasis is within reach because of sustained commitment and investment," said Daniel O'Day, Chairman and Chief Executive Officer, Gilead Sciences. "Through the work to expand access to diagnosis and treatment for the disease, we have already made significant progress in endemic regions. With this expanded collaboration and stronger focus on East Africa, we will accelerate progress toward elimination and help ensure more people can access the care they need to survive.” As part of this collaboration, Gilead will donate more than 400,000 vials of AmBisome® (amphotericin B) liposome for injection and $9.2 million in financial support through 2030. Gilead’s donations will support countries representing approximately 74% of the global VL burden, including Bangladesh, Ethiopia, Eritrea, India, Kenya, Nepal, Somalia, South Sudan, Sudan, Uganda and Yemen, with expanded support in Chad and Djibouti. "This agreement underscores the power of strategic partnerships in advancing global health priorities. Through our collaboration with Gilead Sciences, WHO is better equipped to support countries in accelerating the elimination of visceral leishmaniasis as a public health problem," said Dr Jeremy Farrar, Assistant Director-General, Health Promotion, Disease Prevention and Care, WHO. "Over the next five years, this collaboration will help expand access to essential tools, foster innovation, and reinforce health systems where the burden is greatest. It reflects our shared determination to translate commitment into measurable impact, ensuring that no community is left behind in the fight against neglected tropical diseases." Since the start of the elimination program in Southeast Asia in 2005, this longstanding partnership with WHO has helped reduce new cases of VL by more than 95% in that region, significantly lowering the overall disease burden. In 2023, Bangladesh achieved a major milestone, with WHO validating the elimination of VL as a public health problem. Gilead is committed to advancing global health equity at scale, particularly for neglected diseases in low- and middle-income countries. Through sustained, multiyear approaches including partnerships, voluntary licensing, and targeted access initiatives, Gilead expands access to medicines, strengthens health systems, and addresses serious diseases affecting communities with the greatest unmet need. By fostering innovative collaborations, the company supports sustainable health outcomes worldwide. Visceral leishmaniasis (VL), also known as kala-azar, is a severe parasitic disease endemic in approximately 80 countries worldwide and is the second deadliest parasitic disease after malaria. Transmitted through the bite of infected sandflies carrying the Leishmania parasite, VL attacks internal organs and can cause prolonged fever, weight loss, enlargement of the spleen and liver, and anemia, while increasing vulnerability to other life-threatening infections. If left untreated, VL is fatal in more than 95% of cases. It disproportionately affects people in some of the world's poorest regions and is closely linked to risk factors such as malnutrition, overcrowding, poor housing and sanitation, population displacement, environmental changes, weakened immune systems, and limited access to healthcare. AmBisome® (amphotericin B) liposome for injection is indicated in the U.S. for the treatment of visceral leishmaniasis. In immunocompromised patients with VL treated with AmBisome®, relapse rates were high following initial clearance of parasites. AmBisome® is contraindicated in those patients who have demonstrated or have known hypersensitivity to amphotericin B deoxycholate or any other constituents of the product unless, in the opinion of the treating physician, the benefit of therapy outweighs the risk. Anaphylaxis has been reported with amphotericin B deoxycholate and other amphotericin B-containing drugs, including AmBisome®. If a severe anaphylactic reaction occurs, the infusion should be immediately discontinued and the patient should not receive further infusions of AmBisome®. See the full Prescribing Information for additional important safety information and recommended usage. Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19, cancer and inflammation. In 2025, Gilead announced a planned $32 billion investment to further strengthen its U.S. footprint to power the next era of discovery, jobcreation and public health preparedness – while continuing to invest globally to ensure patients everywhere benefit from its scientific innovation. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, Calif. The content above comes from the network. if any infringement, please contact us to modify.

Drug Approval

16 Apr 2026

·www.biospace.com

Elion Therapeutics Announces Initiation of Turletricin (EL219) Phase 2 Study in Invasive Mould Infection

- Turletricin Granted Qualified Infectious Disease Product (QIDP) and Fast Track Designations by FDA - - Elion to Present Turletricin Clinical Data at ESCMID Global - BOSTON, April 15, 2026 (GLOBE NEWSWIRE) -- Elion Therapeutics, a biotechnology company dedicated to transforming the treatment of life-threatening fungal infections, today announced the initiation of its Phase 2 clinical trial evaluating turletricin (study drug EL219) early antifungal therapy in study participants with suspected and confirmed invasive mould infection (“TREAT-1”). Invasive mould infection (IMI) can cause severe or life-threatening illness in study participants with weakened immune systems, and early treatment is critical for improved patient outcomes. “The QIDP designation and initiation of the TREAT-1 study, with its novel design, represents a key milestone for turletricin and underscores its distinctive potential as a once-weekly, broad-spectrum, non-nephrotoxic polyene antifungal used early in people with suspected IMI,” said Dr. Kieren Marr, CEO of Elion Therapeutics. “Because delayed antifungal therapy is associated with poor outcomes in those who lack adequate immune responses, we are eager to progress enrollment towards demonstrating the potential advantages of weekly turletricin compared to the current standard of care.” The Phase 2 global TREAT-1 clinical trial is a multicenter, randomized, double-blind study evaluating the safety and efficacy of turletricin versus standard of care for early antifungal therapy in study participants with suspected and confirmed IMI. The primary outcome measure is all-cause mortality at Day 21 in the Intent-to-Treat (ITT) analysis set. Additional details are available on ClinicalTrials.gov (NCT07215273). Turletricin has been granted Qualified Infectious Disease Product (QIDP) and Fast Track designations for early antifungal therapy and treatment of invasive aspergillosis by the U.S. Food and Drug Administration (FDA). These designations are intended to support the development of new therapies that address serious or life-threatening infections. QIDP designation provides incentives for the development of new infectious disease technologies, including priority review and eligibility for an additional five years of market exclusivity. On Saturday, April 18 th , the company will present data on turletricin at the 2026 Congress of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID Global), one of the world’s leading congresses in clinical microbiology and infectious diseases in Munich, Germany. The presentation will highlight the early clinical findings supporting turletricin’s potential as a broad-spectrum, novel analog of amphotericin B (AmB) that has been rationally designed to mitigate systemic toxicities. Title: Turletricin (EL219/SF001) a novel, once-weekly, non-nephrotoxic polyene antifungal takes a novel clinical trial approach Date/Time: Saturday, April 18 at 3:00 p.m. CEST Location: Innovation and Pipeline Theatre ABOUT INVASIVE FUNGAL INFECTIONS (IFIs) More than 150 million people suffer from serious fungal infections worldwide. Severe, life-threatening fungal infections result in approximately 2.5 million annual deaths globally. IFIs typically occur in individuals with compromised immune systems due to multiple conditions, including HIV/AIDS, cancer therapies or organ transplants, and severe lung disease. Only four classes of antifungal drugs are currently available, and antifungal resistance, organ toxicities, and drug-drug interactions complicate IFI treatment. The only systemic polyene antifungal is amphotericin B (AmB), a highly efficacious natural product widely used since the 1950s. Various different lipid formulations of AmB have been used to mitigate the severe toxicities caused by AmB, which most commonly include renal toxicity, electrolyte wasting, anemia and inflammatory infusion reactions. These formulations still cause toxicities, and clinical use is further limited by daily intravenous infusion. ABOUT TURLETRICIN (EL219) Turletricin is a next-generation AmB derivative that is engineered to be less toxic to the kidneys. In contrast to AmB, which targets human cholesterol as well as fungal ergosterol, turletricin is selective to fungal ergosterol, mitigating renal toxicity while retaining broad spectrum antifungal activity. Phase 1 studies in healthy volunteers and in people with moderate and severe renal insufficiency have shown turletricin to be well-tolerated with no adverse findings related to renal toxicity. Phase 2 clinical trials of turletricin in adult participants with suspected fungal infections and cryptococcal meningitis are ongoing. ABOUT ELION THERAPEUTICS Elion Therapeutics is a cutting-edge biotechnology company dedicated to transforming the treatment of life-threatening fungal infections. Elion was founded on the belief that mechanistic insights enable targeted optimizations of natural products. In 2024, Elion closed an $82 million Series B funding round led by Deerfield Management and the AMR Action Fund. Additional investors include Illinois Ventures. For more information, please visit . MEDIA CONTACT Armand Girard at agirard@eliontx.com

100 Deals associated with Amphotericin B

External Link

KEGG	Wiki	ATC	Drug Bank
D00203	Amphotericin B	G01AA03 J02AA01 A01AB04	DB00681

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Aspergillosis	Australia	Southern XP IP Pty Ltd.	15 Jun 2026
Cryptococcosis	Australia	Southern XP IP Pty Ltd.	15 Jun 2026
Leishmaniasis, Visceral	Australia	Southern XP IP Pty Ltd.	15 Jun 2026
Systemic mycosis	Australia	Southern XP IP Pty Ltd.	15 Jun 2026
Leishmaniasis	Japan	Sumitomo Pharma Co., Ltd.	17 Jun 2009
Febrile Neutropenia	Japan	Sumitomo Pharma Co., Ltd.	20 Apr 2006
Candidiasis	Japan	Fuji Pharma Co., Ltd.	31 Jan 1997
Invasive Fungal Infections	Japan	Clinigen KK	18 Apr 1963
Mycoses	-	Bristol Myers Squibb Co.	01 Jan 1958
Complicated urinary tract infection	China	-	-
Endocarditis, Bacterial	China	-	-
Meningitis	China	-	-
Sepsis	China	-	-

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Meningitis, Cryptococcal	Phase 3	-	Matinas BioPharma Nanotechnologies, Inc.	01 Jan 2023
Lung Diseases	Phase 3	United States	Enzon Pharmaceuticals, Inc.	01 Oct 2005
Candidiasis, Invasive	Phase 2	-	CSPC Zhongqi Pharmaceutical Technology (Tianjin) Co., Ltd.	01 Jan 2020
Invasive aspergillosis	Phase 2	-	CSPC Zhongqi Pharmaceutical Technology (Tianjin) Co., Ltd.	01 Jan 2020
Acute Lymphoblastic Leukemia	Phase 2	-	Matinas BioPharma Nanotechnologies, Inc.	01 Aug 2019
Acute Myeloid Leukemia	Phase 2	-	Matinas BioPharma Nanotechnologies, Inc.	01 Aug 2019
Candidiasis, Vulvovaginal	Phase 2	United States	Matinas BioPharma Nanotechnologies, Inc.	01 Nov 2016
Yeast infection	Phase 2	United States	Matinas BioPharma Nanotechnologies, Inc.	01 Nov 2016
Candidiasis, Chronic Mucocutaneous	Phase 2	United States	Matinas BioPharma Nanotechnologies, Inc.	27 Sep 2016
Candidiasis, Oral	Phase 2	United States	Bristol Myers Squibb Co.	31 Aug 2001

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05865743 (PERSuaDER, Pubmed \| Trials)	Phase 3	Esophageal Carcinoma	854	SDD prophylaxis	jhzdpdjzyb(tiklzezkej) = pdvtzkzpki xwoinjwpjs (emhsbfkaxl )	Positive	04 Dec 2025
Pubmed \| Infect Drug Resist Manual	Not Applicable	Lung Diseases, Fungal	32	ABCD nebulized inhalation combined with intravenous injection	ncuuvxijsl(tvgwdwufyh) = slightly lower in the combined therapy group than in the intravenous therapy group (1675 vs 1800, P=0.611), although the difference was not statistically significant. ftxxonaooa (ymqjmmvgdm ) View more	Positive	01 Jul 2025
				ABCD intravenous injection
NCT04059770 (CTgov)	Phase 2	Histoplasmosis \| Acquired Immunodeficiency Syndrome	118	single dose of L-AmB (Single Dose of L-AmB)	bbwtgrkfqk = iheverpagw qrruxydnyc (pkrtlwwklx, pmjyflijfz - jqufabusss) View more	-	14 Mar 2025
				2 doses of L-AmB (2 Doses of L-AmB)	bbwtgrkfqk = lxsavuggir qrruxydnyc (pkrtlwwklx, mqxherffki - blxmzlgwyg) View more
NCT06376201 (NEWS) Manual	Phase 4	Invasive Fungal Infections	55	两性霉素B胆固醇硫酸酯复合物	epvmoujotd(aronhxlist) = wrehezzrxu uupxcxfxii (svfqqknpay ) View more	Positive	11 Mar 2025
NCT04031833 (ISRCTN72509687, Pubmed \| Clin Infect Dis)	Phase 1/2	Meningitis, Cryptococcal human immunodeficiency virus (HIV)	498	Liposomal Amphotericin B	brzfylyjrd(uaxgvxttet) = kzahqpicns jdbvytvbln (geuyyofzem, 0.355 - 0.634) View more	Positive	05 Feb 2025
				Amphotericin B Deoxycholate	brzfylyjrd(uaxgvxttet) = kujvofnvhn jdbvytvbln (geuyyofzem, 0.360 - 0.445) View more
NCT02629419 (CAMB, CTgov)	Phase 2	Candidiasis, Chronic Mucocutaneous	4	MAT2203	rnukznjqww = vgofmjnnlh sqjlmujvpr (ljhhuicmcl, hetxnwcsrn - wkfvxghpsm) View more	-	07 Jun 2024
EHA2024	Not Applicable	Hematologic Neoplasms	21	Liposomal Amphotericin B (L-AMB) (Group A (poor response to other antifungal drugs))	thswqaukme(fzecrikazk) = pdxlfgaoor spgvzsjccd (gxwhxnshme )	Positive	14 May 2024
				Liposomal Amphotericin B (L-AMB) (Group B (cannot tolerate adverse reactions))	thswqaukme(fzecrikazk) = fyjzxblloq spgvzsjccd (gxwhxnshme )
GlobeNewswire Manual	Not Applicable	Fusariosis	3	MAT2203	chyntznqpp(ydyzvzniub) = eyxlcexhyh apldloieyy (fecvdacnfq )	Positive	22 Mar 2024
GlobeNewswire Manual	Not Applicable	Invasive Fungal Infections	19	MAT2203	pktpawuyyh(gnfuoxrdeg) = rkvcuonbof ucceoeiniy (flxchidbjz ) View more	Positive	26 Feb 2024
NCT04031833 (Pubmed \| Clin Infect Dis)	Phase 1/2	Meningitis, Cryptococcal	80	Oral LNC Amphotericin B + Flucytosine	yrufcjmskl(dkabdqemzf) = tvzbgtnltp qrgdykdfcj (ppifjqkilc ) View more	-	22 Aug 2023
				IV Amphotericin + Flucytosine	yrufcjmskl(dkabdqemzf) = kclmkbjeky qrgdykdfcj (ppifjqkilc ) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis